This study demonstrates that sulindac sulfide, the active metabolite of sulindac which is known to exhibit anti-neoplastic activity in human and experimental models of colon cancer, also downregulates Sp1, Sp3, Sp4 and pro-oncogenic Sp-regulated genes in colon cancer cells. Here, TFF2 is linked to colonic neoplasm.